Purdue Pharma Canada Expresses Disappointment in reaction to Health Canada decision to not proceed with proposed regulations requiring tamper resistance for Oxycodone

Purdue Pharma Canada is disappointed by the decision and subsequent statement issued by Health Canada on April 4^th, 2016 to not proceed with the proposed regulations requiring tamper resistance for oxycodone.  We continue to believe products with features designed to deter misuse, abuse and diversion, can and do have a positive impact on public health, based on the abundance of published evidence.
According to the news:

The basis of the decision appears not to have taken into account the wealth of available published evidence and therefore, we believe that Health Canada’s statement that: “Specifically, requiring tamper-resistant properties on all legitimate preparations of controlled-release oxycodone would have served to eliminate certain lower cost drugs from the market, increasing costs for patients and the health system, while having little to no effect in the fight against problematic opioid use” is fundamentally flawed. Additionally, it runs counter to the all-party consensus from the last Parliament of Canada, as well as the approach and policies of the United States Food and Drug administration (U.S. FDA).

Click here to view the full report.